Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
5(38%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_4
1
8%
Ph phase_2
1
8%
Ph not_applicable
9
69%
Ph phase_3
2
15%

Phase Distribution

0

Early Stage

1

Mid Stage

3

Late Stage

Phase Distribution13 total trials
Phase 2Efficacy & side effects
1(7.7%)
Phase 3Large-scale testing
2(15.4%)
Phase 4Post-market surveillance
1(7.7%)
N/ANon-phased studies
9(69.2%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

5

trials recruiting

Total Trials

13

all time

Status Distribution
Active(7)
Completed(3)
Other(3)

Detailed Status

Completed3
Active, not recruiting3
unknown3
Recruiting2
Not yet recruiting2

Development Timeline

Analytics

Development Status

Total Trials
13
Active
5
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (7.7%)
Phase 32 (15.4%)
Phase 41 (7.7%)
N/A9 (69.2%)

Trials by Status

recruiting215%
completed323%
active_not_recruiting323%
not_yet_recruiting215%
unknown323%

Recent Activity

5 active trials
Showing 5 of 13
not_yet_recruitingnot_applicable

A Multicenter, Randomized, Open-label, Controlled Study of HAIC Combined With Camrelizumab and Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma With High-risk Recurrence Factors

NCT07618546
active_not_recruitingphase_2

SUrGery With or Without dARolutamide in High-risk and/or Locally Advanced Prostate Cancer

NCT05826509
active_not_recruitingnot_applicable

Femoral Bone Metastases

NCT01428895
not_yet_recruitingnot_applicable

Intrathoracic Chemotherapy for TETs With Pleural Spread or Recurrence (CHOICE-2)

NCT07383142
recruitingnot_applicable

Preventing Recurrences of Chronic Subdural Hematoma in Adult Patients by Middle Meningeal Artery Embolization

NCT05327933
View all 13 trials

Clinical Trials (13)

Showing 13 of 13 trials
NCT07618546Not Applicable

A Multicenter, Randomized, Open-label, Controlled Study of HAIC Combined With Camrelizumab and Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma With High-risk Recurrence Factors

Not Yet Recruiting
NCT05826509Phase 2

SUrGery With or Without dARolutamide in High-risk and/or Locally Advanced Prostate Cancer

Active Not Recruiting
NCT01428895Not Applicable

Femoral Bone Metastases

Active Not Recruiting
NCT07383142Not Applicable

Intrathoracic Chemotherapy for TETs With Pleural Spread or Recurrence (CHOICE-2)

Not Yet Recruiting
NCT05327933Not Applicable

Preventing Recurrences of Chronic Subdural Hematoma in Adult Patients by Middle Meningeal Artery Embolization

Recruiting
NCT03669432Not Applicable

To Study the Impact of Radiation Treatment After Surgery in Patient With Locally Advanced Thyroid Cancer.

Active Not Recruiting
NCT04777942Not Applicable

Neo-TACE-HAIC for High-risk BCLC A Stage HCC (NeoconceptA)

Recruiting
NCT04181931Not Applicable

Neo-TACE-HAIC for PVTT-HCC

Unknown
NCT04424043Not Applicable

Neo-TACE-HAIC for BCLC B Stage HCC

Unknown
NCT02500654Phase 4

Regenerative Surgical Treatment of Peri-implantitis

Completed
NCT02668263Not Applicable

Investigating the Use of Drains and (Internal) Quilting Sutures on Seroma Formation Following Mastectomy

Unknown
NCT00152230Phase 3

A Randomized Controlled Study of Postoperative Adjuvant Chemotherapy of Uracil- Tegafur (UFT) Compared With Surgery Alone (NSAS-CC)

Completed
NCT00152243Phase 3

A Randomized Controlled Study of Postoperative Adjuvant Chemotherapy of Uracil- Tegafur (UFT) Compared With Surgery Alone (NSAS-GC)

Completed

All 13 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
13